Feature | Osteoarthritis (OA) | Rheumatoid Arthritis (RA) |
---|---|---|
Pathogenesis | 🔹 **Mechanical | |
🔸** wear and tear destroys articular cartilage (degenerative joint disorder)→ Inflammation with inadequate repair (mediated by chondrocytes). | 🔹 Autoimmune | |
🔸 Inflammation induces formation of pannus (proliferative granulation tissue) which erodes articular cartilage and bone. (more on pathogenesis below) 🔽 | ||
Predisposing Factors | 🔹 Age. | |
🔹 Female. | ||
🔹 Obesity. | ||
🔹 Joint trauma. | 🔹 Female | |
🔹 Tobacco smoking | ||
🔹 HLA-DR4 (4-walled “rheum”). | ||
🔹 HLA-DRB1. | ||
🔹 Auto antibodies→ Detected by ELLISA | ||
🔸 Rheumatoid factor → IgM antibody targeting IgG Fc region; in 80%. | ||
🔸 Anti-cyclic citrullinated peptide antibody→ more specific. | ||
Presentation | 🔹 Joint pain |
🔸 Pain in weight-bearing joints after use (e.g., at the end of the day).
🔸 Can have morning stiffness but less than 30 min.
🔸 Improves with rest.
🔸 Asymmetric joint involvement.
🔹Systemic symptoms 🔸 Absent 🔹 Knee cartilage loss begins medially (“bowlegged”). | 🔹 Joint Pain 🔸 Morning stiffness lasting > 1 hour. 🔸 Pain improves with use. 🔸 Symmetric joint involvement. 🔹 Systemic symptoms 🔸 Present→ fever, fatigue, weight loss. 🔹 Extraarticular manifestations common. | | Joint Findings | 🔹 Bone 🔸 Osteophytes (bone spurs). 🔸 Loose bodies. 🔸 Subchondral sclerosis and cysts. 🔹 Joint space 🔸 Joint space narrowing (asymmetric). 🔹 Hand 🔸 Heberden nodes (at DIP) 🔸 Bouchard nodes (at PIP) 🔸 And 1st CMC; not MCP 🔹 Extra 🔸 Synovial fluid noninflammatory (WBC < 2000/mm³) | 🔹 Bone 🔸 Erosions. 🔸 Juxta-articular osteopenia. 🔸 Subchondral cysts. 🔹 Joint space 🔸 Joint space narrowing (symmetric). 🔹 Hand 🔸 Ulnar finger deviation 🔸 Swan neck 🔸 Boutonniere. 🔸 Involves MCP, PIP not DIP or 1st CMC. 🔹 Extra 🔸 Cervical subluxation 🔸 Soft tissue swelling | | Treatment | 🔹 Activity modification. 🔹 Acetaminophen. 🔹 NSAIDs. 🔹 Intra-articular glucocorticoids. | 🔹 NSAIDs. 🔹 Glucocorticoids. 🔹 Disease-modifying agents (e.g., methotrexate, sulfasalazine). 🔹 Biologic agents (e.g., TNF-α inhibitors).
→ DMAs takes time to show relief unlike glucocorticoids (rapid acting). |
<aside> 💡 Extraarticular Manifestations of Rheumatoid Arthritis
<aside> 🧠
Pathogenesis of RA
**Pathophysiology of osteoarthritis**
Pathophysiology of rheumatoid arthritis
Affected hand joints in RA vs OA
Heberden nodes
Bouchard nodes
Hand deformities of RA
Rheumatoid nodules with ulnar deviation
Left index finger dactylitis